CHP
RIGL icon

Cable Hill Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Cable Hill Partners’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-100
Closed -$4K – 938
2017
Q4 		$4K Buy
+100
New +$3.81K ﹤0.01% 788

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Cable Hill Partners's RIGL Position: Q1 2018 in Review

Cable Hill Partners sold out of Rigel Pharmaceuticals (RIGL) in Q1 2018, closing a stake of 100 shares — an estimated $4K sold.

Cable Hill Partners first reported a position in RIGL in Q4 2017 and held it in 1 quarter. The position peaked at $4K in Q4 2017. 117 funds tracked by Wall St. Rank hold RIGL as of Q1 2018.

  • Cable Hill Partners reported no remaining Rigel Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Cable Hill Partners sold 100 Rigel Pharmaceuticals shares in Q1 2018, an estimated $4K.
  • Cable Hill Partners first reported a position in Rigel Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Cable Hill Partners's Rigel Pharmaceuticals position peaked at $4K in Q4 2017.
  • 117 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2018.

Based on Cable Hill Partners's 13F filing for Q1 2018, filed 20 Apr 2018.